CRNX
NASDAQ
US
Crinetics Pharmaceuticals, Inc. - Common Stock
$37,23
▲ +$0,66
(+1,80%)
Vol 1.2M
2
Skor Kualitas
fail
Pendapatan ✗
Laba Bersih ✗
>IPO ✗
Kap. Pasar
$4.4B
ROE
-35,1%
Margin
-22312,8%
D/E
0,00
Beta
0,19
52W
$24–$55
Konsensus Wall Street
22 analis · Apr 20267
Beli Kuat
13
Beli
2
Tahan
0
Jual
0
Jual Kuat
90,9%
Peringkat Beli
Grafik Harga
Saham Serupa
BLTE
Belite Bio Inc
$5.6B
TERN
Terns Pharmaceuticals Inc
$4.3B
CORT
Corcept Therapeutics Inc
P/E 34,5
$3.7B
LGND
Ligand Pharmaceuticals Inc
P/E 76,6
$3.7B
AMRX
Amneal Pharmaceuticals Inc
P/E 671,4
$4.0B
INDV
Indivior Pharmaceuticals, Inc
P/E 35,8
$4.5B
GPCR
Structure Therapeutics Inc
$4.2B
EWTX
Edgewise Therapeutics Inc
$2.6B
LQDA
Liquidia Corp
$3.0B
TARS
Tarsus Pharmaceuticals Inc
$3.5B
Pendapatan
Tingkat beat: 25,0%
Laporan Berikutnya
Mei 06, 2026
Estimasi EPS: $-1,25
| Kuartal | EPS Estimasi | EPS Aktual | Kejutan |
|---|---|---|---|
| Mar 2026 | $-1,25 | — | — |
| Des 2025 | $-1,39 | $-1,29 | +$0,10 |
| Sep 2025 | $-1,28 | $-1,38 | $-0,10 |
| Jun 2025 | $-1,12 | $-1,23 | $-0,11 |
Pendapatan & Laba Kuartalan
| Kuartal | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|
| Pendapatan | — | $361K | $1.0M | $143K | $6.2M |
| Laba Bersih | -$80.6M | -$96.8M | -$115.6M | -$130.1M | -$122.8M |
Tren Fundamental
| Metrik | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -32.3% | -32.3% | -32.3% | -32.3% | -35.1% | -35.1% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -11216.0% | -15259.4% | -15259.4% | -15259.4% | -22312.8% | -22312.8% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 17.80 | 17.80 | 17.80 | 17.80 | 15.12 | 15.12 |
Rasio Utama
ROA (TTM)
-32,0%
P/S (TTM)
2877,66
P/B
3,6
EPS (TTM)
$-4,53
CF/Share
$-3,61
Pertumbuhan Pendapatan 3T
-1,3%
52W High
$54,78
52W Low
$24,10
$24,10
Rentang 52 Minggu
$54,78
Kesehatan Keuangan
Arus Kas Bebas
-$93.4M
Utang Bersih
-$53.0M
Kas
$101.5M
Total Utang
$48.5M
Per tanggal Des 31, 2025
Як CRNX виглядає на тлі конкурентів у Pharmaceuticals?
Група порівняння: Mid-cap Pharmaceuticals ($2B+) · 25 компаній
Оцінка CRNX vs аналоги Pharmaceuticals
P/E
—
▼
0%
di bawah
rekan
(30,7)
vs Rekan
vs Industri
Nilai wajar
P/S
2877,7
▲
42722%
di atas
rekan
(6,7)
vs Rekan
vs Industri
Overvalued
P/B
3,6
▼
31%
di bawah
rekan
(5,2)
vs Rekan
vs Industri
Lebih mahal
Дивідендна дохідність
—
▼
0%
di bawah
rekan
(3,1%)
vs Rekan
vs Industri
Yield rendah
Прибутковість CRNX vs аналоги Pharmaceuticals
ROE
-35,1%
▼
35%
di bawah
rekan
(-26,1%)
vs Rekan
vs Industri
Lemah
Net margin
-22312,8%
▼
1538716%
di bawah
rekan
(-1,5%)
vs Rekan
vs Industri
Lemah
Валова маржа
—
▼
0%
di bawah
rekan
(88,9%)
vs Rekan
vs Industri
Tingkat atas
ROA
-32,0%
▼
239%
di bawah
rekan
(-9,5%)
vs Rekan
vs Industri
Lemah
Фінансове здоровʼя CRNX vs аналоги Pharmaceuticals
D/E ratio
0,0
▼
100%
di bawah
rekan
(27,4)
vs Rekan
vs Industri
Utang rendah
Поточна ліквідність
15,1
▲
335%
di atas
rekan
(3,5)
vs Rekan
vs Industri
Likuiditas kuat
Beta
0,2
▼
68%
di bawah
rekan
(0,6)
vs Rekan
vs Industri
Lebih volatil
Радар фундаменталів CRNX
CRNX
Median rekan
Industri
CRNX прибутковість vs борг
Розмір бульбашки = капіталізація · X = чиста маржа · Y = D/E ratio
CRNX vs аналоги: ключові метрики
Aktivitas Orang Dalam
NeutralPembelian
0
Penjualan
0
BETZ STEPHEN F
Officer · Mar 16
10612 shs
STRUTHERS RICHARD SCOTT
Chief Executive Officer · Mar 16
21981 shs
KNIGHT JEFF E
Chief Operating Officer · Mar 16
9911 shs
VIVALDI COELHO ROGERIO
Director · Mar 12
5000 shs
SCHILKE TOBIN
Chief Financial Officer · Mar 03
6713 shs
OKEY STEPHANIE S
Director · Mar 03
3000 shs
SCHILKE TOBIN
Chief Financial Officer · Feb 23
32000 shs
STRUTHERS RICHARD SCOTT
Chief Executive Officer · Feb 23
62000 shs
KNIGHT JEFF E
Chief Operating Officer · Feb 23
34000 shs
BETZ STEPHEN F
Officer · Feb 23
30000 shs
Terakhir 90 hari
Pemegang Terbesar
Top 5: 44,3%FMR, LLC
13,65%
$481.3M
Vanguard Group Inc
8,72%
$307.6M
Wellington Management Group…
7,68%
$270.6M
Blackrock Inc.
7,63%
$269.0M
Farallon Capital Management…
6,62%
$233.4M
Per tanggal Des 31, 2025
Berita Terbaru
Belum ada berita terkait